NCT05525728 (SENSORIEL2) is a NA clinical trial of Neurosensory in Dizziness; Syndrome, sponsored by University Hospital, Caen.

Who is sponsoring NCT05525728?

NCT05525728 is sponsored by University Hospital, Caen.

What drugs are being tested in NCT05525728?

Interventions in NCT05525728: Neurosensory.

What condition does NCT05525728 study?

NCT05525728 studies Dizziness; Syndrome.

Is NCT05525728 still recruiting?

NCT05525728 is currently status unknown. Last updated 2 September 2022.

Last reviewed 2022-09-02 · How we verify

NCT05525728: SENSORIEL2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Integrative Study of Vestibular Pathology

Status unknown NA Last updated 2 September 2022

What this trial tests

NA trial testing Neurosensory in Dizziness; Syndrome in 80 participants. Status unknown.

Timeline

18 June 2022

Primary endpoint
31 January 2026

31 January 2026

Quick facts

Lead sponsor	University Hospital, Caen
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	80
Start date	18 June 2022
Primary completion	31 January 2026
Estimated completion	31 January 2026
Sites	2 locations across France

Drugs / interventions tested

Neurosensory

Conditions studied

Dizziness; Syndrome — all drugs for Dizziness; Syndrome →

Sponsor

University Hospital, Caen

Who can join

Adults 18 to 80, any sex, with Dizziness; Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Exploratory posturological, neurosensory, cognitive, emotional, personality and general evaluations (quality of life). The investigators will characterize a sensory profile quantified by one or more scores from a multi-parameter baysian approach. Each parameter and these scores will be correlated to the type of vestibular damage and its recovery in order to establish diagnostic, prognostic and therapeutic follow-up markers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University Hospital, Caen trials

Trials by the same sponsor.

NCT07406737 — Feasibility and Outcomes Registry of Lumenless dEfibrillation Leads for Conduction System Pacing · not yet recruiting
NCT06639750 — Respiratory Microbioma and Respiratory Complications After Hematopoietic Stem Cell Transplantion · not yet recruiting
NCT07467031 — Bachstim Registry: a Feasability Study of Bachmann's Area Pacing · not yet recruiting
NCT07477132 — A Dose-response Study to Determine the Right Dosage of Sugammadex as a Reversal Agent of Rocuronium in Infants Between 1 · Phase 4 · not yet recruiting
NCT07520578 — EFFECTIVENESS OF EARLY INFORMATION AND ENDORSMENT BY GP TO INCREASE COLONOSCOPY FOLLOW-UP AND REDUCE DELAYS IN PEOPLE WI · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05525728 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Caen
Last refreshed: 2 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05525728.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing